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ABSTRACT
Introduction: Combinations of newer antidepressants and second-generation antipsychotics
(SGAs)

are

frequently

used

by

clinicians.

Pharmacokinetic

and

poorly

understood

pharmacodynamic drug interactions can occur between them. Areas covered: Limited
pharmacodynamic drug interaction information and pharmacokinetic drug interaction studies are
comprehensively reviewed. Expert opinion: More pharmacokinetic drug interaction studies are
needed for better establishing dose correction factors after adding fluoxetine and paroxetine to
aripiprazole, iloperidone and risperidone. More pharmacokinetic drug interaction studies and case
reports are needed for better establishing the need for dose correction factors after adding i)
fluoxetine to clozapine, lurasidone, quetiapine and olanzapine; ii) paroxetine to olanzapine; iii)
fluvoxamine to asenapine, aripiprazole, iloperidone, lurasidone, olanzapine, quetiapine and
risperidone; iv) high sertraline doses to aripiprazole, clozapine, iloperidone and risperidone: v)
bupropion and duloxetine to aripiprazole, clozapine, iloperidone and risperidone; and vi) asenapine
to paroxetine and venlafaxine. Possible beneficial pharmacodynamic drug interaction effects occur
after adding SGAs to newer antidepressants for treatment-resistant major depressive and obsessivecompulsive disorders. The lack of studies combining newer antidepressants and SGAs in psychotic
depression is worrisome. Pharmacodynamic drug interactions between newer antidepressants and
SGAs may be more likely for mirtazapine and bupropion. Adding selective serotonin reuptake
inhibitors (SSRIs) and SGAs may increase QTc interval and may very rarely contribute to torsades
de pointes.
Keywords:

newer

antidepressants,

pharmacodynamics, pharmacokinetics

second-generation

antipsychotics,

drug

interactions,
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Highlights box
- Drug-drug interactions between newer antidepressants and second-generation antipsychotics
(SGAs) are frequently clinically relevant.
- More pharmacokinetic drug interaction studies are needed for better establishing dose correction
factors after adding fluoxetine and paroxetine to aripiprazole, iloperidone and risperidone.
- More pharmacokinetic drug interaction studies and case reports are needed for better establishing
the need for dose correction factors after adding i) fluoxetine to clozapine, lurasidone, quetiapine
and olanzapine; ii) paroxetine to olanzapine; iii) fluvoxamine to asenapine, aripiprazole,
iloperidone, lurasidone, olanzapine, quetiapine and risperidone; iv) high sertraline doses to
aripiprazole, clozapine, iloperidone and risperidone; v) bupropion and duloxetine to aripiprazole,
clozapine, iloperidone and risperidone; and vi) asenapine to paroxetine and venlafaxine.
- The pharmacodynamic science of drug interactions between newer antidepressants and SGAs is in
its infancy.
- There are possible beneficial pharmacodynamic drug interaction effects after adding SGAs to
newer antidepressants for treatment-resistant major depressive disorder and obsessive-compulsive
disorder (OCD). The lack of studies in psychotic depression using combinations of newer
antidepressants and SGAs is worrisome.
- Pharmacodynamic drug interactions between newer antidepressants and SGAs may be more likely
for mirtazapine and bupropion. Clinicians need to remember that adding selective serotonin
reuptake inhibitors (SSRIs) and SGAs may risk an increase in QTc interval and very rarely
contribute to torsades de pointes.
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1. Introduction
Drugs used for the treatment of depressive disorders are usually classified into older or
classic agents, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors
(MAOIs), and newer antidepressants, such as selective serotonin reuptake inhibitors (SSRIs),
serotonin and noradrenaline reuptake inhibitors (SNRIs) and other antidepressants with variable
mechanisms of action 1. Over the past two decades, newer antidepressants, particularly SSRIs,
have gradually replaced TCAs as drugs of choice for the management of depressive disorders,
mainly because of their improved tolerability and safety profile. Some newer antidepressants are
also approved for the treatment of other psychiatric conditions including anxiety disorders,
obsessive compulsive disorder, eating disorders, and various forms of chronic pain such as diabetic
neuropathic pain and fibromyalgia 1.
Antipsychotic drugs can be similarly divided into traditional or first-generation
antipsychotics (FGAs) and atypical or second-generation antipsychotics (SGAs) 2. In recent
years, SGAs have become the mainstream treatment intervention for patients with schizophrenia
and bipolar disorder, due to a lower risk for acute and chronic extrapyramidal symptoms and
prolactin elevation, as compared to traditional antipsychotics. They are also increasingly used to
treat a variety of psychiatric and neurological disorders including mental and behavioral disorders
in dementia, psychosis associated with Parkinson's disease, treatment-resistant obsessivecompulsive disorder (OCD), and aggressive behavior 3. However, antiserotonergic SGAs, such as
clozapine, appear to be associated with a risk of inducing or aggravating obsessive-compulsive
symptoms in schizophrenia 4.
Newer antidepressants and SGAs are often prescribed together in patients with concomitant
psychotic and depressive symptoms, such as those with schizoaffective disorder 5 or psychotic
depression 6. Moreover, antidepressants, mainly SSRIs, may be used as an adjunctive strategy for
the treatment of negative symptoms of schizophrenia 7, 8. On the other hand, SGAs may be added
to antidepressants in patients with refractory OCD 9-11 and in those with treatment-resistant
major depressive disorder 12-14. In this respect, aripiprazole and quetiapine extended-release
received United States (US) Food and Drug Administration (FDA) approval as add-ons for patients
with major depressive disorder, while the combination olanzapine-fluoxetine was approved for
treatment-resistant depression.
In view of the frequent co-prescription of newer antidepressants and SGAs, sometimes for
the purpose of augmentation, information on potential drug interactions between these compounds
is important for safe prescribing. While certain drug combinations may prove beneficial and,
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therefore, may be used advantageously in clinical practice, in many cases they may be harmful,
resulting in either decreased efficacy or increased risk of adverse drug reactions (ADRs).
In recent years, a number of comprehensive reviews of clinically relevant DIs involving
newer antidepressants 15-18 or SGAs have been published 19-22. The aim of the present article
is to provide an updated review of clinically significant drug interactions between newer
antidepressants and SGAs.
Articles for this review were obtained from a PubMed search with no time limit. Searches
were performed for each of the newer antidepressants and SGAs. Only articles published in peerreviewed journals were included, while meeting abstracts were excluded. Information was also
obtained from the individual product inserts of each newer antidepressant or SGA. Additional drug
interaction information was also obtained from citations of the articles that were retrieved during
our search, and these were also included in our review. This search was beyond the articles
previously found and listed in the authors’ published literature reviews [16, 19] and drug interaction
studies.

2. Basic mechanisms of drug interactions between newer antidepressants and
SGAs
Based on their mechanisms, drug interactions are usually divided into two categories,
pharmacokinetic and pharmacodynamic.
2.1 Pharmacokinetic drug interactions
Pharmacokinetic drug interactions consist of changes in the absorption, distribution,
metabolism or excretion of a drug and/or its metabolite(s) after the addition of another drug. These
drug interactions are easily verified by a change in plasma drug concentrations, usually called
therapeutic drug monitoring (TDM). Pharmacokinetic parameters of newer antidepressants and
SGAs are summarized in Tables 1 and 2, respectively.
Drug interactions can occur at the gastrointestinal level when medications are administered
orally, which is always the case with newer antidepressants and frequent with SGAs. To our
knowledge, no interaction at the oral absorption level has been described so far between these two
drug types.
Protein binding displacement interactions may theoretically occur between newer
antidepressants and SGAs, as many of these agents are highly bound to plasma proteins (>90%).
Competition between two drugs for binding sites on plasma proteins may cause a rise in the free
fraction of the displaced drug in plasma or tissue, thereby potentially increasing its pharmacological
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effects [23]. However, unless additional mechanisms are at work, these interactions are usually not
clinically relevant, because the free drug is rapidly cleared from the plasma.
Most pharmacokinetic drug interactions between newer antidepressants and SGAs occur at a
metabolic level and usually involve the hepatic cytochrome P450 (CYP) system and, to a lesser
extent, the uridine diphosphate glucuronosyltransferase (UGT) system 24. In recent years, the in
vitro characterization of the major drug-metabolizing enzymes, in particular the human CYP
system, with identification of substrates, inhibitors, and inducers of different CYP isoforms, has
greatly improved the prediction of metabolic drug interactions, providing an invaluable resource in
helping to anticipate and avoid potential drug interactions [24]. In principle, concomitant treatment
with drugs metabolized by the same enzyme or coadministration of a drug with another medication
acting as an inhibitor or inducer involves the risk of a drug interaction. The potential occurrence and
clinical significance of a metabolic drug interaction will then depend on a variety of drug-related
(i.e., potency and concentration/dose of the inhibitor/inducer, therapeutic index of the substrate,
extent of metabolism of the substrate through the affected enzyme, presence of active metabolites),
patient-related (i.e., age, genetic predisposition) and environmental factors (i.e., smoking) [23]. As
shown in Tables 1 and 2, newer antidepressants and SGAs (with the exception of amisulpride and
paliperidone) are extensively metabolized via CYPs or UGTs. As many compounds of these two
therapeutic classes share common metabolic pathways, potential metabolically-based drug
interactions may be anticipated. Furthermore, some newer antidepressant agents act as inhibitors of
various CYPs and may therefore impair the elimination of antipsychotic agents metabolized via
these isoforms 15, 16, 18.

On the other hand, most SGAs appear to be neither inhibitors nor

inducers of the major drug-metabolizing enzymes 19, 21; only asenapine may have weak
CYP2D6 inhibitory properties that may become clinically relevant in some circumstances 25, 26.
Drug interactions at the renal excretion level are probably not relevant because both newer
antidepressants and SGAs are mainly eliminated by drug metabolism.
Pharmacokinetic drug interactions between newer antidepressants and SGAs may also
involve drug transporters, in particular P-glycoprotein (P-gp), which plays an important role in the
absorption, distribution and excretion of a wide variety of therapeutic agents 27. P-gp is encoded
by the ATP-binding cassette sub-family B member 1 (ABCB1) gene. It is a multidrug efflux
transporter highly expressed in the small intestine, brain, liver and kidney. It acts as a natural
defense mechanism against several drugs by limiting their absorption from the gut and penetration
into the brain and promoting their elimination in the bile and urine. A number of newer
antidepressants, including the SSRIs fluoxetine, fluvoxamine, paroxetine and sertraline 28, as well
as many SGAs, such as risperidone, paliperidone, olanzapine, aripiprazole and ziprasidone, are
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substrates of P-gp 29. Moreover, in vitro studies have indicated that some newer antidepressants,
namely paroxetine, fluvoxamine and sertraline, and the SGAs olanzapine and risperidone may also
act as P-gp inhibitors 30. Based on this evidence, it cannot be excluded that some
pharmacokinetic drug interactions between newer antidepressants and SGAs, currently attributed to
metabolic enzyme inhibition, may also be explained by P-gp inhibition.
2.2 Pharmacodynamic drug interactions
Most articles reviewing drug interactions ignore the pharmacodynamic mechanisms of
newer antidepressants and SGAs, which are poorly understood. This subsection provides a very
brief reference to the pharmacodynamics of antidepressants and SGAs; they are described more
comprehensively in Figures 1 to 4 and their detailed footnotes. At the end of this section, a
subsection comments on the types of pharmacodynamic drug interactions.
2.2.1 Antidepressant pharmacodynamics
Figure 1 summarizes antidepressant mechanisms of action in several disorders including
depression, OCD, anxiety, pain, and weight loss.

Textbooks usually report that most new

antidepressants act by inhibiting reuptake transporters, but they also usually acknowledge that this
is not a definitively proven theory, since the chronology of reuptake inhibition does not match the
chronology of antidepressant response. SSRIs include fluoxetine, paroxetine, fluvoxamine,
sertraline, citalopram and escitalopram; the name SSRI indicates that they mainly inhibit serotonin
transporters. SNRIs inhibit both serotonin and noradrenaline transporters and include venlafaxine,
desvenlafaxine, duloxetine, levominalcipran, and milnacipran. Other newer antidepressants with
different mechanisms of action include reboxetine, bupropion, vilazodone, vortioxetine,
mirtazapine, and agomelatine. Reboxetine is a selective noradrenaline transporter inhibitor.
Bupropion is an inhibitor of noradrenaline and dopamine transporters. There is no agreement in the
literature about mirtazapine’s mechanism of action. Vilazadone [31] and recently-introduced
vortioxetine [32] have SSRI properties and also are antagonists of some serotonin receptors.
Vilazadone is also a 5-HT1A receptor antagonist and vortioxetine is also a 5-HT3A and 5-HT7
receptor antagonist, a 5-HT1B receptor partial agonist, and a 5-HT1A receptor agonist (Figure 1,
footnote 3). Labbate et al. [33] list mirtazapine as an alpha 2 (α2) adrenergic receptor antagonist but
also recognize that it has 5-HT2A and 5-HT2C antagonist properties. Other articles and/or textbooks
endorse other variants of this theory. Agomelatine is a melatonergic analogue drug acting as
MT1/MT2 agonist and a 5-HT2C antagonist [34].
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Nefazadone and trazadone are not included in order to simplify this article. Nefazadone is
no longer used and trazadone is frequently used as a hypnotic rather than an antidepressant agent.
Figure 2 summarizes antidepressant mechanisms of action associated with major safety
issues.
2.2.2 SGA pharmacodynamics
Figure 3 summarizes SGA mechanisms of action, explaining their efficacy in schizophrenia,
other psychoses and other psychiatric disorders [35]. In summary, the majority of the SGAs are
dopamine 2 receptor (D2) antagonists including amisulpride, asenapine, clozapine, iloperidone,
lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone, while aripiprazole is
a D2 partial agonist. Many SGA ADRs are explained by their blockade of neurotransmitter
receptors (Figure 4).
2.2.3. Pharmacological knowledge and pharmacodynamic drug interactions
Pharmacodynamic drug interactions take place directly at the site of action of a drug or
indirectly by interfering with another physiological mechanism. They result in a modification of the
pharmacological action of a drug without any change in the plasma concentration and are more
difficult to identify and measure than pharmacokinetic drug interactions. These drug interactions
can be additive (i.e., equal to the sum of the effects of the individual drugs), synergistic (i.e., the
combined effects are greater than expected from the sum of individual effects) or antagonistic (i.e.,
the combined effects are less than additive) [23]. They can be associated with positive effects
(increased efficacy and/or safety) or negative effects (decreased efficacy and/or safety).

3. Specific drug interactions between newer antidepressants and SGAs
3.1 Pharmacokinetic interactions
3.1.1 Effect of newer antidepressants on the pharmacokinetics of SGAs
3.1.1.1 SSRIs
At the present, SSRIs are the most widely prescribed antidepressants. They may cause
clinically relevant, dose-dependent inhibition of various CYPs. The six marketed compounds differ
considerably in their potency to inhibit individual CYP isoenzymes 16, 36.
Fluoxetine
Fluoxetine and its metabolite norfluoxetine are potent inhibitors of CYP2D6 and moderate
inhibitors of CYP2C9, while they mildly to moderately affect the activity of CYP2C19 and
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CYP3A4 16, 36. Based on this, fluoxetine is expected to interfere with the elimination of SGAs
metabolized via these CYP isoforms.
Early pharmacokinetic studies had documented that fluoxetine may impair the elimination
of clozapine resulting in an increase of approximately 40-70% of its plasma concentrations in
patients concomitantly treated with fluoxetine 20 mg/day 37, 38. In a subsequent investigation,
the effect of an 8-week treatment with fluoxetine (20 mg/day) on plasma concentrations of
clozapine and its active metabolite norclozapine was evaluated in 10 schizophrenic patients
stabilized on clozapine therapy (200-450 mg/day) 39. During fluoxetine administration, mean
plasma concentrations of clozapine and norclozapine increased significantly (p<0.01) by 58% and
36%, respectively. A study controlling other variables estimated that fluoxetine increases plasma
clozapine concentration by 36% on average, which requires multiplying the clozapine dose by 0.73
to compensate [40]. This interaction may be attributed to the inhibitory effect of fluoxetine on the
activity of CYP2D6, CYP2C19 and CYP3A4, which play an important role in clozapine
metabolism. In addition, norfluoxetine, the major metabolite of fluoxetine, may also contribute to
this interaction as a moderate inhibitor of CYP3A4.
A clinically relevant pharmacokinetic drug interaction may occur between fluoxetine and
risperidone. In an open-label study involving 10 schizophrenic patients stabilized on risperidone (46 mg/day), coadministration of fluoxetine (20 mg/day) for 4 weeks caused a significant elevation
(by 75%; p<0.01) of plasma concentration of the active fraction of risperidone (risperidone plus 9hydroxyrisperidone) 41. One patient dropped out after one week of combination treatment due to
occurrence of akathisia, while two patients developed parkinsonian symptoms, thus requiring
anticholinergic medication. Bondolfi et al. 42 investigated the pharmacokinetics of risperidone (4
or 6 mg/day) before and during coadministration of fluoxetine (20 mg/day) in 11 psychotic
inpatients, 8 of which were extensive metabolizers (EM) and 3 poor metabolizers (PM) for
CYP2D6. The area under the plasma concentration/time curve (AUC) of the active moiety of
risperidone increased from 470.0  170.0 ng.h/ml to 663.0  243.3 ng.h/ml (p<0.05) and from
576.3  19.6 ng.h/ml to 788.0  89.1 ng.h/ml (not significant) in EMs and PMs, respectively. This
interaction is presumably due to inhibition of CYP2D6, the major isoenzyme responsible for the 9hydroxylation of risperidone, although it is possible that norfluoxetine may also inhibit CYP3A4,
blocking both metabolic pathways for risperidone. A reduction in risperidone dosage is advisable in
case of concomitant administration of fluoxetine.
Coadministration of fluoxetine, 60 mg/day, given for eight days to 15 non-smoking healthy
volunteers caused a statistically significant, but clinically insignificant, change in the
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pharmacokinetic profiles of a single 5 mg dose of olanzapine 43. Olanzapine plasma clearance
decreased by 15% (p<0.01) and peak plasma concentration (Cmax) increased by 18% (p<0.01).
In a study of 13 patients with various psychiatric disorders treated with quetiapine, 300 mg
twice daily, the addition of fluoxetine, 60 mg/day, for only 8 days did not substantially alter the
AUC0-12 h and the Cmax of quetiapine 44. A large TDM study provided similar results, showing
that concomitant administration with fluoxetine did not affect dose-normalized serum
concentrations of quetiapine 45.
In patients comedicated with CYP2D6 inhibitors (including 9 subjects on fluoxetine) dosenormalized serum concentrations of aripiprazole were 45% higher compared with controls
(p<0.05), while those of the active metabolite, dehydroaripiprazole were unchanged 46. As
aripiprazole is metabolized by CYP2D6 and CYP3A4, the inhibitory effect of fluoxetine on the
activity of these two isoforms may account for the observed changes.
Iloperidone is metabolized by CYP2D6 and CYP3A4. According to its prescribing
information, coadministration of fluoxetine (20 mg twice daily for 21 days) and a single 3 mg
iloperidone dose to 23 EM healthy volunteers increased the AUC of iloperidone and its main
metabolite P88 by about 2-3 fold, and decreased the AUC of its metabolite P95 by one-half.
Iloperidone doses should be reduced by one-half when administered with fluoxetine 25, 26.
A recent case report documented the occurrence of a glossopharyngeal dystonia following
coadministration of fluoxetine with lurasidone 47. This effect was attributed to the inhibitory
action of fluoxetine and norfluoxetine on CYP3A4-mediated biotransformation of lurasidone.
Paroxetine
Paroxetine is a potent inhibitor of CYP2D6, while it only minimally affects other CYPs 16,
36.
Paroxetine effects upon risperidone disposition were documented in two clinical
pharmacokinetic investigations 48, 49. In the first study involving 10 schizophrenic patients
stabilized on risperidone therapy (4-8 mg/day), coadministration of paroxetine (20 mg/day) for 4
weeks resulted in a mean, statistically significant increase by 45% (p<0.05) in plasma
concentrations of the active fraction of risperidone 48. The drug combination was well tolerated
with the exception of one patient who developed extrapyramidal symptoms in the second week of
adjunctive therapy. In the second study, 12 schizophrenic patients receiving risperidone 4 mg/day
were, in addition, treated with incremental doses of paroxetine for 12 weeks (10, 20 and 40 mg/day
for 4 weeks each) 49. Paroxetine resulted in a dose-dependent increase in risperidone and active
moiety

plasma

concentrations

without

changing

9-hydroxyrisperidone

levels.

Plasma

concentrations of risperidone active moiety were not increased during paroxetine 10 mg/day (1.3-

12
fold, not significant) or 20 mg/day (1.6-fold, not significant) dosing, but were significantly
increased by 1.8-fold (p<0.05) during paroxetine 40 mg/day dosing. This pharmacokinetic
interaction is probably explained by the inhibitory effect of paroxetine on the CYP2D6-mediated 9hydroxylation of risperidone. An initial low dose of paroxetine (10 or 20 mg/day) may be safe
whenever paroxetine is coadministered with risperidone.
Data concerning the possibility of a metabolic interaction between paroxetine and clozapine
are contradictory. Some studies have documented a moderate elevation of plasma clozapine
concentrations (by approximately 20-40%), presumably not associated with clinically relevant
effects, following administration of therapeutic doses of paroxetine, 20 mg/day 38, 50. A study
controlling other variables estimated that paroxetine increased plasma clozapine concentration on
average by 30% which requires multiplying the clozapine dose by 0.77 to compensate [38]. This
effect has been attributed to the inhibition of CYP2D6, an isoform which is partially responsible for
clozapine biotransformation. Conversely, another investigation has documented only minor,
insignificant changes in serum concentrations of clozapine and its metabolites during concomitant
treatment with paroxetine 51.
As expected, data from a TDM study indicated that dose-normalized serum concentrations
of quetiapine, a CYP3A4 substrate, did not change during coadministration with paroxetine 45.
The possibility of a pharmacokinetic drug interaction between paroxetine and aripiprazole
has recently been documented. Fourteen Japanese patients with schizophrenia, treated with
aripiprazole (24 mg/day in 5 cases, 12 mg/day in 5 cases, and 6 mg/day in 4 case) for at least 2
weeks, received paroxetine 10 mg/day during the first week and 20 mg/day during the second week
52. Plasma concentrations of aripiprazole increased significantly (p<0.05) during coadministration
of both paroxetine 10 mg/day (1.5-fold) and paroxetine 20 mg/day (1.7-fold) as compared to
baseline, whereas plasma concentrations of its active metabolite, dehydroaripiprazole, were
unchanged throughout the study period. Plasma concentrations of the sum of aripiprazole and its
active metabolite during coadministration of paroxetine 10 and 20 mg/day were also significantly
(p<0.05) higher (1.4-fold and 1.5-fold) than those before paroxetine coadministration. These effects
are probably due to the potent inhibitory effect of paroxetine on CYP2D6, the isoform responsible,
together with CYP3A4, for aripiprazole biotransformation. Consistent with these findings, in a
study of healthy subjects, coadministration of paroxetine (20 mg/day) decreased systemic clearance
of aripiprazole by 58 and 23% in CYP2D6 EMs and intermediate metabolizers (IMs), respectively,
demonstrating that the percentage of inhibition of CYP2D6 activity by coadministration of
paroxetine was apparently greater in CYP2D6 EMs than in IMs 53.
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Iloperidone dose should be reduced by 50% during coadministration with CYP2D6
inhibitors such as paroxetine 25, 26.
Fluvoxamine
Fluvoxamine influences the activity of various CYP isoenzymes; it is a potent inhibitor of
CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, while it affects
CYP2D6 activity only slightly 16, 36. Being an inhibitor of different CYP isoforms, fluvoxamine
may impair the elimination of various SGAs.
The pharmacokinetic drug interaction between fluvoxamine and clozapine has been
extensively investigated. Formal kinetic studies and case reports have demonstrated that
concomitant administration of fluvoxamine (50-100 mg/day) may cause a 5-10-fold increase in
plasma concentrations of clozapine, along with signs of toxicity (nausea, dizziness, extrapyramidal
symptoms) 51, 54-58. This drug interaction has been attributed not only to the inhibition of
CYP1A2, the major enzyme responsible for clozapine metabolism, but also to the additional
inhibitory effects of fluvoxamine on CYP2C19 and CYP3A4, which also contribute to its
biotransformation 59. Clinicians should be aware of a drug interaction between clozapine and
fluvoxamine. Downward dosage adjustments of clozapine may be necessary. However, given the
magnitude of this interaction, a pharmacokinetic augmentation strategy has been proposed for the
co-administration of fluvoxamine with low doses of clozapine 57, 60-62. Clinicians using that
strategy should use TDM and have a high level of pharmacokinetic expertise.
Several studies have documented that fluvoxamine (50-100 mg/day) may also elevate
plasma levels of olanzapine approximately 2-fold, presumably through inhibition of CYP1A2, with
possible ADR occurrence 63-66. The magnitude of the effect of fluvoxamine on plasma levels of
olanzapine is lower than observed with clozapine, as olanzapine is metabolized by multiple enzyme
systems, namely UGT, whose activity may not be affected by fluvoxamine. The combination of
olanzapine and fluvoxamine should be used cautiously and with TDM to avoid olanzapine ADRs
(sedation, orthostatic hypotension, tachycardia, transaminase elevations, or seizures). Similar to the
fluvoxamine-clozapine combination, a low dose of fluvoxamine (25 mg/day) has been proposed as
an adjunct to reduce olanzapine dose requirements as a cost-saving measure 67.
D’Arrigo et al. 68 evaluated the possibility of a metabolic drug interaction between
fluvoxamine and risperidone in schizophrenic patients on a chronic treatment with risperidone, 3-6
mg/day. While in the 6 patients receiving adjunctive treatment with fluvoxamine 100 mg/day no
significant modifications in plasma levels of risperidone and its active metabolite were observed,
concentrations increased slightly but significantly (by a mean of 26% over pretreatment; p<0.05) in
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the subgroup of 5 subjects treated with a final fluvoxamine dose of 200 mg/day. A dose-dependent
inhibitory effect of fluvoxamine on CYP2D6- and/or CYP3A4-mediated 9-hydroxylation of
risperidone provides a rational explanation for this drug interaction.
In a large routine TDM program for quetiapine, concomitant administration with
fluvoxamine was associated with a significant increase in quetiapine serum concentration-dose
(C/D) ratio (p<0.001) 45. This pharmacokinetic drug interaction may be explained by the
inhibitory effect of fluvoxamine on the CYP3A4-mediated metabolism of quetiapine.
In an open-label investigation in healthy subjects, coadministration of fluvoxamine (100
mg/day) resulted in a 40% decrease in the systemic clearance of a single 3 mg oral dose of
aripiprazole, suggesting inhibition of CYP3A4-mediated biotransformation of aripiprazole by
fluvoxamine 53.
In healthy volunteers, during combined administration with a single 5 mg sublingual dose of
asenapine, a novel antipsychotic partially metabolized by CYP1A2, fluvoxamine 25 mg twice a day
resulted in a 29% increase in asenapine AUC 25, 26. The full therapeutic dose of fluvoxamine
would be expected to produce a greater increase in plasma asenapine concentrations. Therefore,
coadministration of asenapine and fluvoxamine should be approached with caution.
Sertraline
Sertraline is a mild to moderate in vitro inhibitor of CYP2D6 and a weak inhibitor of the
other CYP isoenzymes 16, 36.
In an open-label pharmacokinetic investigation involving 11 patients with schizophrenia or
schizoaffective disorder stabilized on risperidone therapy (4-6 mg/day), co-medication with
sertraline, 50 to 100 mg/day, for 8 weeks did not significantly change steady-state plasma
concentrations of risperidone active fraction 69. However, in the 2 patients receiving the highest
dose of sertraline, 150 mg/day, at week 8 total plasma risperidone concentrations were increased
by 36% and 52% respectively, as compared to baseline values, presumably due to a dose-dependent
inhibition of CYP2D6-mediated 9-hydroxylation of risperidone.
Early clinical pharmacokinetic studies documented that sertraline, at dosages ≤100 mg/day,
did not significantly affect plasma concentrations of clozapine and its major metabolite
norclozapine 38, 50. On the other hand, two case reports have documented a moderate increase in
plasma concentrations of clozapine after coadministration with sertraline at doses of 50 and 300
mg/day, respectively 70, 71.
In a placebo-controlled study in patients with schizophrenia and comorbid major depression,
the addition of sertraline, 50 to 100 mg/day, to antipsychotic monotherapy caused minimal but not
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clinically significant changes in serum levels of various SGAs, including risperidone and
olanzapine, which were comparable to those observed in placebo-treated patients 72. In three
different TDM studies, concomitant intake of sertraline was found not to affect dose-normalized
serum concentrations of olanzapine 63, quetiapine 45, and aripiprazole 46.
Citalopram/Escitalopram
Citalopram and its active S-enantiomer, escitalopram, are weak in vitro inhibitors of
CYP2D6 and are negligible inhibitors of CYP1A2, CYP2C9, CYP2C19 and CYP3A4 73, 74. Due
to their minimal effect on drug-metabolizing enzymes, citalopram and escitalopram are not
expected to cause clinically relevant drug interactions with SGAs.
Concomitant administration of citalopram (20-40 mg/day) was found not to modify steadystate plasma concentrations of clozapine and norclozapine, as reported in two early studies in
patients with schizophrenia 75, 76. No changes in steady-state plasma concentrations of
risperidone and 9-hydroxyrisperidone were observed in 7 patients after administration of citalopram
40 mg/day 76. By using a mixed model to estimate the effects of comedications on plasma
olanzapine concentrations, Botts et al. found that concomitant medication with citalopram did not
affect plasma concentrations of olanzapine 77. In a study from a large routine TDM service, dosecorrected quetiapine serum concentrations were slightly (by 16%), but significantly (p<0.05),
higher in patients comedicated with citalopram/escitalopram 45. However, due to the limited
increase in quetiapine concentrations and its wide therapeutic index, quetiapine dose adjustment is
not considered necessary if citalopram or escitalopram are coadministered. In a routine TDM
program for patients treated with aripiprazole, steady-state dose-adjusted serum concentrations of
aripiprazole and the sum of aripiprazole and dehydroaripiprazole were approximately 20% higher
(p<0.05) in patients comedicated with escitalopram (n=26) than in subjects in the monotherapy
group (n=60) 46. The small, though significant, elevation of aripiprazole concentrations may be
attributed to the weak inhibitory effect of escitalopram on CYP2D6, which plays a role in the
biotransformation of aripiprazole.

3.1.1.2 SNRIs
This section includes venlafaxine, desvenlafaxine, and duloxetine studies. To our
knowledge, no study has investigated the effect of levomilnacipran and milnacipran on the SGA
pharmacokinetics.
Venlafaxine/Desvenlafaxine
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According to in vitro studies, venlafaxine is a weaker CYP2D6 inhibitor than paroxetine,
fluoxetine, fluvoxamine and sertraline, and has minimal or no effect on the activity of CYP1A2,
CYP2C9 and CYP3A4 78. Desvenlafaxine, venlafaxine active metabolite, has no inhibitory effect
on the activity of the major CYP isoforms 78.
There is limited data on the effects of venlafaxine and desvenlafaxine on SGA metabolism.
In a study of 30 healthy volunteers, treatment with venlafaxine, 150 mg/day for 9 days, caused
minimal, presumably not clinically relevant, changes in the pharmacokinetics of a single 1 mg oral
dose of risperidone, a CYP2D6 substrate 79. Plasma concentrations of clozapine were measured
in 11 schizophrenic male patients with depressive symptoms who were administered both
clozapine and venlafaxine 80. Low to moderate doses of venlafaxine did not significantly affect
plasma clozapine levels. Data from TDM studies documented that concomitant administration with
venlafaxine was associated with no changes in dose-normalized serum concentrations of quetiapine
45 nor in those of aripiprazole and its active metabolite dehydroaripiprazole 46.
Duloxetine
Duloxetine is a moderate inhibitor of CYP2D6, while it has minimal or no effect on the
activity of CYP1A2, CYP2C9, CYP2C19, and CYP3A4 81.
Two open-label prospective trials evaluated the potential drug interaction between
duloxetine and SGAs in patients with psychotic disorders 82, 83. In the first study involving 20
in- or outpatients on antipsychotic medication, the addition of duloxetine (mean final dosage of 83.3
 26.3 mg/day) over a period of 6 weeks resulted in an increase of dose-corrected serum levels of
olanzapine in three patients, while serum levels of clozapine remained substantially unchanged in
eleven subjects 82. In the second trial, administration of duloxetine, 60 mg/day for up to 6 weeks,
to 20 outpatients stabilized on clozapine (n=6), olanzapine (n=8) or risperidone (n=7), did not
modify the plasma concentrations of clozapine and olanzapine, which are not CYP2D6 substrates,
while it was associated with a modest, but potentially clinically significant, increase in the plasma
concentration of the active moiety of risperidone (by a mean 26%), presumably through inhibition
of CYP2D6-mediated 9-hydroxylation of risperidone 83. On the other hand, in a study based on a
TDM database, coadministration of duloxetine, 30-120 mg/day, was not associated with significant
effects on the serum concentrations of both risperidone and aripiprazole, another CYP2D6 substrate
84.

3.1.1.3 Other newer antidepressants
Reboxetine
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Reboxetine has only weak CYP inhibitory effects 85. Therefore, reboxetine is not expected
to impair SGA elimination. In agreement with this, an open-label pharmacokinetic investigation in
14 patients with schizophrenia or schizoaffective disorder with associated depressive symptoms,
documented no effect of a 4-week adjunctive treatment with reboxetine 8 mg/day on the plasma
concentrations of clozapine (250-500 mg/day, n = 7), risperidone (4-6 mg/day, n = 7) and their
main metabolites 86.
Mirtazapine
According to in vitro studies, mirtazapine has minimal inhibitory effects on the various CYP
isoforms and appears to carry a low risk for drug interactions 87. In a pilot study involving 6
psychiatric patients treated with risperidone (2-6 mg/day), the addition of mirtazapine, 30 mg/day
for 2-4 weeks, did not modify plasma concentrations of risperidone and its active 9-hydroxy
metabolite 88. A subsequent open-label investigation evaluated the effect of mirtazapine, 30
mg/day for 6 weeks, on steady-state plasma concentrations of various SGAs in 24 patients with
chronic schizophrenia 89. Adjunctive mirtazapine resulted in minimal and statistically
insignificant changes in the mean plasma concentrations of clozapine (200-650 mg/day, n = 9),
risperidone (3-8 mg/day, n = 8), olanzapine (10-20 mg/day, n = 7), and their major metabolites
during the study period, indicating lack of pharmacokinetic drug interaction between mirtazapine
and these SGAs. By using data from a routine TDM service, concomitant intake of mirtazapine
(n=12) did not significantly affect serum concentrations of aripiprazole or dehydroaripiprazole 46.
Bupropion, agomelatine, vilazodone or vortioxetine
There is no documentation of pharmacokinetic drug interactions between bupropion,
agomelatine, vilazodone or vortioxetine and SGAs. As bupropion is a moderate inhibitor of
CYP2D6, it should interfere with the elimination of SGAs partly metabolized by CYP2D6:
risperidone, aripiprazole and iloperidone.
3.1.2 Effect of SGAs on the pharmacokinetics of newer antidepressants
As SGAs, except for asenapine, do not significantly affect the activity of CYP isoenzymes,
they are not expected to impair the elimination of newer antidepressants in usual circumstances 19,
21, 25, 26. On the other hand, any substrate competes with others for the corresponding enzyme
and inhibits it; the potency of the inhibition is influenced by substrate affinity and dose. In most
clinical situations competitive inhibition is probably irrelevant. In unusual polypharmacy situations,
adding a competitive inhibitor (such as SGAs which are not normally considered inhibitors) in a
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patient taking a drug with a narrow therapeutic window may affect another drug’s drug metabolism,
due to inhibitor accumulation past the tipping point 35.
In a large investigation including two open-label, non-randomized studies in healthy
subjects and two placebo-controlled studies in patients with major depressive disorder, adjunctive
treatment with aripiprazole caused no meaningful effects on the pharmacokinetics of citalopram,
fluoxetine, paroxetine, sertraline or venlafaxine in either healthy subjects or patients 90.
Asenapine is a weak inhibitor of CYP2D6 and should be administered with caution with
drugs that are substrates for this isoform. In this respect, coadministration of paroxetine and
asenapine has been shown to cause a nearly 2-fold increase in paroxetine exposure 25, 26.
3.2 Pharmacodynamic interactions
3.2.1. Pharmacodynamic drug interactions increasing efficacy
According to a meta-analysis of adjunctive therapy for depression, aripiprazole, olanzapine
(combined with fluoxetine), quetiapine and risperidone showed small to moderately significant
effects on clinician-rated depression severity measures when compared to adding placebo with
limited benefits but increased ADRs 91. These positive randomized clinical trials (RCTs) suggest
that SGAs may have a synergistic effect and increase the antidepressant response in patients taking
antidepressants for major depressive disorder.
There are very few randomized RCTs on psychotic depression [6]. These RCTs suggested a
synergistic effect between antipsychotic and antidepressant co-treatment since the combination
appeared superior to monotherapy of either drug class. However, most of the RCTs have used
TCAs rather than the newer antidepressants; some of them used FGAs. Therefore, there is little
information to guide clinicians if they decide to combine newer antidepressants and SGAs for
psychotic depression [92].
The idea of combining fluoxetine and olanzapine in pill form would suggest that they have
additive or synergistic effects in bipolar depression. A meta-analysis indicates some increase of
efficacy, but ADRs were frequent [93].
A SGA meta-analysis of OCD studies suggested some evidence that adding quetiapine or
risperidone to antidepressants increases efficacy [94]. Therefore, the limited data from RCTs do
not allow commenting on whether SGAs may have additive or synergistic effects on OCD when
added to SSRIs. On the other hand, clinical guidelines after lack of response to SSRIs usually
recommend SGAs as one of the options.
A meta-analysis indicated that adding newer antidepressants to antipsychotics may reduce
negative symptoms [8]. Other articles reviewed proposed that the α2 antagonist properties of some
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newer antidepressants such as mirtazapine may explain the improvement of negative symptoms
[95].
3.2.2. Pharmacodynamic drug interactions decreasing efficacy
There is very limited RCT data on maintenance treatment after bipolar depression [96] but
there is general agreement that some antidepressants may increase the switch to mania, whereas
bupropion and SSRIs may have fewer risks than TCAs and SNRIs [97]. A meta-analysis suggested
that mood stabilizers may not prevent the switch to mania but too few SGA studies have been
conducted to establish certainty [98]. Future studies will need to verify whether antidepressants
decrease the mood-stabilizing properties of SGAs by increasing mania-switching or not.
3.2.3. Pharmacodynamic drug interactions increasing safety
As bupropion treatment can be associated with weight loss, one can propose that adding it to
SGAs may decrease the risk of weight gain from SGAs, but there are no related RCTs in PubMed.
Figure 2 indicates that epidemiological studies definitively establish SSRIs as producing a
small increased risk for abnormal bleeding by depleting platelets from serotonin, particularly when
other risk factors are present. SGAs, particularly clozapine, appear to increase the risk of
developing venous thromboembolism by poorly understood mechanisms, including enhancing
platelet aggregation [99]. From a pharmacological point of view one could hypothesize that the
combination

may

decrease

the

risk

of

SSRI-induced

bleeding

or

clozapine-induced

thromboembolism, but we know too little about the pharmacodynamic mechanisms; there is no
published data to support this idea.
Reviews of serotonin syndrome [100, 101] do not usually list SGAPs as drugs contributing
to serotonin syndrome, but the case report literature is much more complicated. Case reports
suggest that some SGAs may decrease the risk for serotonin syndrome while other SGAs may
increase the risk for serotonin syndrome. In that sense ziprasidone may be a special case, since it
can inhibit serotonin reuptake and has been proposed as the single agent causing serotonin
syndrome in one case [102] and as a contributing factor in two others [103, 104]. Other cases
suggest that withdrawal from olanzapine [105] or clozapine [106] may have contributed to
serotonin syndrome. Another case suggested that aripiprazole may have protected against serotonin
syndrome [107].
3.2.4. Pharmacodynamic drug interactions decreasing safety
Figures 2 and 4 indicate that some newer antidepressants and some SGAs share ADRs but,
as far as we know, no studies have been published on the combined increased risk of ADRs, other
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than the previously mentioned study that the olanzapine-fluoxetine combination is associated with
substantial risk of ADRs [93].
Pharmacodynamic drug interactions possibly associated with specific newer antidepressant
compounds in combination with SGAs may include increased risk for weight gain, sedation,
hypertension, decreased seizure threshold, psychotic exacerbation, nausea and anticholinergic
ADRs. These possible drug interactions have rarely been studied in the literature, but they can be
hypothesized based on pharmacological knowledge. Most SGAs are associated with metabolic
ADRs (Figure 4); therefore, mirtazapine (and to a lesser degree paroxetine) probably has an
additive risk for metabolic ADRs. Mirtazapine is also likely to increase the risk of sedation in
patients taking SGAs.
SNRIs are associated with tachycardia and all except for duloxetine with hypertension.
Clozapine is the only SGA that is associated with hypertension (usually <5%). It is likely that the
SNRI-clozapine combination may increase the risk for tachycardia and/or hypertension. Most SGAs
are associated with increased seizure risk (Figure 4); thus, adding bupropion may further increase
that risk.
Bupropion may also exacerbate the risk of psychosis in patients taking SGAs. In smoking
cessation trials in schizophrenia, bupropion was used for a short time and did not appear to cause
psychotic exacerbations [108]. In a comprehensive review of the use of bupropion in schizophrenia,
Englisch et al. described the risk of bupropion-induced psychosis as negligible [109].
Many newer antidepressants are associated with increased risk of nausea and vomiting
(Figure 2), which may be important to remember when used in combination with three SGAs
associated with nausea: aripiprazole, lurasidone and ziprasidone (Figure 4). Increased risk for
antimuscarinic ADRs may occur when combining mirtazapine, paroxetine or reboxetine (Figure 2)
with antimuscarinic SGAs: clozapine, olanzapine or high doses of quetiapine (Figure 4).
Less common pharmacodynamic drug interactions possibly associated with combinations
between newer antidepressants and SGAs may include increased risk for akathisia, sexual ADRs,
long QTc and hepatotoxicity. SSRIs have occasionally been associated with akathisia [110]. Among
SGAs, risperidone is particularly prone to cause extrapyramidal symptoms including akathisia, but
aripiprazole may be prone to cause more akathisia than other SGAs [111]. It will be interesting to
study whether the combination of aripiprazole and akathisia is particularly prone to akathisia or not.
In their review, Kumar and Sachdev [112] indicated that some studies suggest that aripiprazole may
be particularly more prone to cause akathisia in patients taking antidepressants. It is possible that
some SSRIs, due to pharmacodynamic and/or pharmacokinetic drug interactions (e.g., fluoxetine or
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paroxetine are CYP2D6 inhibitors) may contribute to increased akathisia risk in patients taking
aripiprazole.
Sexual ADRs are frequent both with newer antidepressants (not all) (Figure 2) and SGAs.
The literature does not comment on whether the combination increases the risk or not.
Lethal arrhythmias are very complicated to study since these deaths are relatively rare and
are not easily identified in autopsies. Several syndromes are associated with sudden cardiac death.
One of them is Brugada syndrome (see footnote 22 of Figure 2) which has been linked with newer
antidepressants. Another syndrome associated with sudden cardiac death, long QTc syndrome, is
more familiar to psychiatrists and can lead to torsades de pointes. In the 1990s, genetic forms of
long QTc syndrome were found to be channelopathies at the cardiac potassium channels. Most
clinically relevant drug-related QTc prolongations occur via inhibition of the delayed rectifier
potassium current, IKr, a current mediated in humans by the ion channel KCNH2 encoded by the
human ether-a-go-go–related gene (HERG). These prolongations are acquired presentations similar
to one of the genetic forms of the disease [113]. Several psychiatric drugs have warnings for QTc
prolongation; among SGAs iloperidone and ziprasidone appear much more prone to cause QTc
prolongations (Table 4). The FDA has provided a QTc warning regarding the use of high doses of
citalopram (Table 4). Most cases of drug-induced torsades de pointes occur in the context of
substantial prolongation of the QTc interval, typically to values >500 milliseconds, but QTc alone is
a relatively poor predictor of arrhythmic risk in any individual patient. Some drugs that
substantially prolong the QTc interval produce very low rates of torsades de pointes while others
have much smaller QTc effects but are considerably more proarrhythmic [113]. TCAs and some
FGAs, particularly phenothiazines, have been clearly associated with torsades de pointes.
According to a systematic review of case reports, citalopram, fluoxetine and sertraline may be
associated with torsades de pointes [114]. A recent pharmacoepidemiology study suggested that
ziprasidone and amisulpride had potential torsadogenic risk similar to haloperidol [115]; a review
of case reports proposed that risperidone may rarely cause torsades de pointes [116]. The literature
on clinical cases of torsades de pointes is very complex since 1) the cases are frequently associated
with polypharmacy and drug interactions, with a pharmacodynamic component involving multiple
drugs with HERG channel inhibitory properties and sometimes a pharmacokinetic component, an
inhibitor increasing the plasma concentrations of one or several of the drugs [113]; and 2) other risk
factors such as geriatric age, female gender, bradycardia, hypokalemia and hypomagnesemia may
be important, too [117]. The literature does not discuss the combination of newer antidepressants
and SGAs as risk factors for torsades de pointes, but there are two well-controlled SGA studies on
QTc incorporating SSRIs in the design [118, 119]. The addition of paroxetine to iloperidone was
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associated with increased serum iloperidone concentrations and increased QTc; 10% of the patients
had increases ≥ 60 msec but no patient had a QTc ≥ 500 msec [119]. Risperidone with paroxetine
and olanzapine with fluvoxamine were associated with mild increases (<10 msec) in QTc [118].
Agomelatine has been definitively associated with liver enzyme elevations. Most cases
(90%) recover after agomelatine discontinuation but severe forms can also occur [120].
Agomelatine should not be combined with clozapine or olanzapine, the two SGAs most frequently
associated with liver enzyme elevations. In a recent review of antidepressant-induced liver injury,
Voican et al. [121] stated that agomelatine, bupropion and duloxetine are the most frequent of the
newer antidepressants that, on rare occasions, can cause life-threatening hepatotoxicity. They
suggest that duloxetine should not be administered in those with prior liver problems. Therefore,
duloxetine should not be used in those with prior history of liver injury secondary to antipsychotics,
or with current liver enzyme elevations during antipsychotic treatment. Figure 4 describes the safest
newer antidepressants regarding liver injury.

4. Conclusion
Table 4 uses mechanistic pharmacokinetic and pharmacodynamic data which provide a
summary of the most important practical drug interaction information for clinicians and
recommendations for dealing with drug interactions. The authors would have preferred to use an
evidence-based medicine approach in making these recommendations but, unfortunately, most of
the pharmacokinetic drug interaction studies were not completed using clinical doses and durations
relevant for clinicians. There are almost no pharmacodynamic drug interaction studies; therefore,
Table 4 describes pharmacodynamic drug interactions leading to ADRs that can be uncommon or
rare. Statistical theory explains that evidence-based medicine approaches focused on average
patients cannot rule out rare ADRs in outliers not well represented by the average patient [122].
Thus, the idea behind Table 4 is not to convince scientists but to raise clinicians’ awareness of drug
interaction risks and remind them that both pharmacokinetic and pharmacodynamic drug
interactions can contribute to pharmacological actions. The information contained in this article
may not fully account for all of the possible drug interaction risks because of the limited studies
available; so future updating as new information becomes available will be necessary.
4.1 Pharmacokinetic drug interactions and clinical implications
Fluoxetine, fluvoxamine and paroxetine are potent inhibitors that are likely to have
clinically relevant effects on several SGA serum levels (Table 4). Adding any of these potent
inhibitors to a specific SGA is associated with an increase in SGA serum concentration which may
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be associated with ADRs. The discontinuation of these inhibitors may be associated with a decrease
in SGA serum concentration which may be associated with loss of efficacy. On the other hand, if
the patient is taking one of these inhibitors and a SGA with potential to be inhibited needs to be
added, a lower SGA dose may be advisable. The best way to control for these drug interactions is
by checking SGA TDM. When available, as in the cases of clozapine, olanzapine and risperidone, it
may be a good idea to consider it. When SGA TDM is not available, Table 4 provides a best
estimation of a correction factor based on the limited available literature.
The pharmacokinetic drug interactions associated with the milder inhibitors bupropion,
duloxetine or high dosages of sertraline have not been well studied in the literature. Thus, clinicians
may need to be watchful when using them with CYP2D6-dependent SGAs: aripiprazole,
iloperidone and risperidone (Table 4).
The only SGA that may be relevant as an inhibitor is asenapine, which may be a mild
CYP2D6 inhibitor. Consequently, it may present a low drug interaction risk when added to a
CYP2D6-dependent antidepressant: paroxetine or venlafaxine.
4.2 Pharmacodynamic drug interactions and clinical implications
As described, the literature is very limited in the description of pharmacodynamic drug
interactions but in our experience these types of drug interactions are very relevant in clinical
practice (Table 4). Section 3.2.1 describes pharmacodynamic drug interactions that can be
considered positive: the addition of SGAs to newer antidepressants as adjunctive therapy for major
depressive disorder or OCD. These possible additive or synergistic effects are well-known by
clinicians and are not described in Table 4.
Table 4 describes some drug interactions with bupropion and mirtazapine that have not been
well-studied, but are important for clinicians to have in mind. Clinicians considering an
antidepressant in a patient taking clozapine, which has a relatively narrow therapeutic window, may
need to check Table 4 before selecting among the newer antidepressants, since some can increase
clozapine serum levels, some may increase risk of antimuscarinic ADRs and some may increase the
risk of tachycardia and hypertension.
Torsades de pointes is very rare but clinicians adding SSRIs and SGAs may need to
remember that checking QTc in an ECG may be helpful; the literature suggests that cases probably
result from a combination of multiple factors. Clinicians adding SSRIs and SGAs may want to
check for family history of sudden death; personal history of syncopes, arrhythmias or heart
conditions; electrolyte disturbances; and co-prescription of other medications that may increase
QTc (Table 4).
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5. Expert opinion
We have limited understanding of the clinical relevance of drug interactions associated with
the inhibitory properties of fluoxetine, fluvoxamine and paroxetine. Unfortunately, the drug
interaction studies with SGAs are rather limited. Table 4 provides correction factors based on the
limited available literature.

These correction factors were calculated using the available

pharmacokinetic studies which summarize the data, assuming that the average patient represents the
population well; however, there is extensive pharmacokinetic variability between patients, and
TDM measurements are advised for optimal titration of the dosage in each individual. The
correction factors may not fully account for all of the possible risks of treatment because of the
limited studies available; thus, there will be a need to periodically update these correction factors as
new knowledge becomes available. In spite of their limitations, these correction factors are useful
because: 1) many clinicians have no access to antipsychotic TDM and, as a matter of fact, there is
limited clinical data on some SGA TDM (amisulpride, aripiprazole, paliperidone, quetiapine, and
ziprasidone) and published TDM data on three compounds (asenapine, iloperidone and lurasidone)
is virtually absent; and 2) in our experience, having the correction factor helps clinicians to make
decisions. With a correction factor of 5-10, fluvoxamine is a poor antidepressant choice for
clozapine patients unless the clinician has access to TDM and sophisticated pharmacokinetic
knowledge.
Bupropion and duloxetine are moderate CYP2D6 inhibitors but there are almost no DI
studies on SGAPs to verify the clinical relevance of their inhibitory properties for aripiprazole,
iloperidone and risperidone. A serious limitation of the SGA drug interaction literature is the lack of
studies in clinical samples with high doses of sertraline, which may be a CYP2D6 inhibitor only in
high doses. Moreover, in some sensitive patients, high sertraline doses may inhibit other CYPs. The
only SGA that may have some likelihood of being a mild inhibitor is asenapine, which has weak
CYP2D6 inhibitory properties. Other SGAs and newer antidepressants may be clinically relevant
inhibitors in very rare circumstances, but clinicians may need to remember that competitive
inhibition is always possible.
It is not easy to conduct drug interaction studies using clinically relevant doses.
Pharmaceutical companies tend to invest in simple pharmacokinetic drug interaction studies in
volunteers, frequently using single dosing to get approval for the marketing of their drugs, but this
type of pharmacokinetic study rarely reflects clinical practice. Drug interaction data in the
prescribing information (or package inserts) is usually not designed to provide easy helps for
clinicians in correcting pharmacokinetic drug interactions with dose changes. The pharmacokinetic
science on newer antidepressants and SGA combinations may be in its adolescence and needing
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maturation, while pharmacodynamic drug interaction science appears to be in its infancy. None of
the studies combining newer antidepressants and SGAs for greater efficacy in major depressive
disorder or OCD explore whether the combinations are additive or synergistic.
It would be naïve to simply conclude that more studies of newer antidepressant and SGA
drug interactions are needed. They are obviously needed, but the lack of funding for clinical
research is a major limitation. To progress in this area, collaboration from all interested parties is
needed, including: i) drug agencies and pharmaceutical companies; ii) clinicians using newer
antidepressant-SGA combinations; iii) researchers with expertise in a) meta-analyses, b)
pharmacoepidemiology, c) drug interaction pharmacology; and iv) grant agencies.
The FDA may need to think “out of the box” and look for new ways to encourage
pharmaceutical companies possibly interested in marketing new antidepressants and new SGAs for
psychotic depression by providing special “incentives”, assuming the companies seriously want to
study drug interaction issues.
Clinicians frequently co-prescribe newer antidepressants and SGAs. Thousands of US
patients take these combinations. There is great need of naturalistic studies describing possible
additive or synergistic efficacy and, more importantly, the long-term safety of these combinations.
Are early nausea and vomiting more frequent in some of these combinations than in the various
monotherapies?
Researchers with expertise in meta-analysis may need to develop better methods to study the
safety of newer antidepressant and SGA combinations by comparing ADRs in available SGA RCTs
of monotherapy in schizophrenia versus those of adjuvant therapy in major depressive disorder.
Researchers with expertise in pharmacoepidemiology need to explore whether rare ADRs such as
risk of long QTc may be more frequently associated with SSRI-SGA combinations than with
individual drugs. On the other hand, serotonin syndrome may be less frequent in the presence of
SGAs (with the probable exception of ziprasidone) and antipsychotic-induced seizures in the
presence of SSRIs such as fluoxetine, which may decrease seizure threshold in the average patient.
The complexity of pharmacological treatments in the real world cannot be denied since fluoxetine
has on rare occasions been associated with seizures.
Researchers with expertise in in vitro drug interaction studies or in vivo clinical studies
using isotopes to explore drug clearance need to better study the SGA metabolic pathways and how
they change when inhibitors are added, particularly in the complicated conditions used in clinical
practices such as adding both an inducer and an inhibitor to an SGA (e.g., adding carbamazepine
and fluoxetine to risperidone).
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Grant and health agencies need to remember that pragmatic clinical trials are key in treating
complex disorders such as OCD, schizophrenia, psychotic depression and bipolar disorder, where
polytherapy is the norm. Pharmaceutical RCTs do not substitute for long-term pragmatic trials that
may better inform clinicians of the effectiveness of the various types of mono- and polytherapy
frequently used in the real world of clinical practice. Pragmatic trials need to pay better attention to
drug interactions.
Progress in the next few years, if this research agenda is followed, should also be
accompanied by a better continuous medical education on drug interactions and improvements in
psychopharmacology textbooks, so that clinicians begin to pay more attention to pharmacodynamic
and pharmacokinetic drug interactions associated with the frequent co-prescription of newer
antidepressants and SGAs. Well-educated clinicians will help move the research agenda by
publishing drug interaction case reports of unusual combinations and asking for more drug
interaction studies from pharmaceutical companies and researchers.
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Table 1. Pharmacokinetic parameters of newer antidepressants. Based on Refs. 15, 16, 18 and 32.
Bioavailability
(%)

Protein binding
(%)

Half-life
(h)

Metabolism

SSRI
Citalopram
Escitalopram
Fluoxetine

95
80
80

82
56
95

23-45
27
2-4 days

CYP3A4, CYP2C19, CYP2D6
CYP3A4, CYP2C19, CYP2D6
CYP2D6, CYP2C9, CYP2C19,
CYP3A4

Fluvoxamine

<53

77

15-22

CYP1A2, CYP2D6

Paroxetine

>64

93

10-21

CYP2D6 (major), CYP3A4

Sertraline

>44

98

22-36

CYP2C9, CYP2C19, CYP2D6,
CYP3A4

SNRI
Desvenlafaxine

80

30

9-15

Duloxetine
Levomilnacipran

50
92

>90
22

10-12
12

UGT, CYP3A4
Excreted unchanged (45%)
CYP1A2 (major), CYP2D6

Milnacipran

85

13

8-10

CYP3A4 (18%), other CYP
and UGTs
Excreted unchanged (58%)
Glucuronidation (20-30%)
CYP3A4 (10%)
Excreted unchanged (50-60%)

Active metabolites

Norfluoxetine

Inhibitory effect on CYP
isoenzymes
CYP2D6 (weak)
CYP2D6 (weak)
CYP2D6 (potent)
CYP2C9 (moderate)
CYP2C19 and CYP3A4
(weak to moderate)
CYP1A2 (weak)
CYP1A2 and CYP2C19
(potent)
CYP2C9 and CYP3A4
(moderate)
CYP2D6 (weak)
CYP2D6 (potent)
CYP1A2, CYP2C9,
CYP2C19, CYP3A4 (weak)
CYP2D6 (weak to
moderate)
CYP1A2, CYP2C9,
CYP2C19 and CYP3A4
(weak)

CYP2D6 (moderate)

CYP3A4 (weak)
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Venlafaxine
Other newer
antidepressants
Agomelatine
Bupropion

92

27

5

<5
90

95
84

1-2
20

Mirtazapine
Reboxetine
Vilazodone

50
>60
72a

85
97
96-99

20-40
12-16
20-24

Vortioxetine

75

98

57-66

CYP2D6 (major), CYP3A4
CYP1A2 (90%), CYP2C9 (10%)
CYP2B6
CYP2D6, CYP3A4, CYP1A2
CYP3A4
CYP3A4 (major), CYP2C19,
CYP2D6, Carboxylesterase
CYP2D6 (major), CYP3A4,
CYP2C19, CYP2C9, CYP2A6,
CYP2C8, CYP2B6

Desvenlafaxine

Hydroxybupropion
Threohydrobupropion
Erythrohydrobupropion

CYP2D6 (moderate)

CYP2C8 (?)

CYP: Cytochrome P450; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor; UGT: Uridine
diphosphate glucuronosyltransferase.
a

Decreased absorption when not administered with food.
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Table 2. Pharmacokinetic parameters of second-generation antipsychotics. Based on Refs. 19, 21, 22 and 35.
Bioavailability
(%)

Protein
binding (%)

Half-life
(h)

43-48
87
35a
12-81

17
99
95
95

12
48-68
1-2
6-33

Metabolism

Active metabolites

Unchanged renal excretion
CYP2D6, CYP3A4
Dehydroaripiprazole
UGT 1A4, CYP1A2
CYP1A2 (major),
Norclozapine1
CYP2C19, CYP3A4, CYP2D6
96
93
20-24
CYP2D6 (major), CYP3A4
P88,2 P95
Iloperidone
b
99
18
CYP3A4
ID-14823
9-19
Lurasidone
60-80
93
20-70
CYP1A2 (major), UGT1A4,
Olanzapine
CYP2D6, FMO
Paliperidone
28
30
24
Minimal hepatic metabolism
NA
83
5-8
CYP3A4
Norquetiapine
Quetiapine
68
90
3-24
CYP2D6 (major), CYP3A4
9-hydroxyrisperidone
Risperidone
99
4-10
CYP3A4, Aldehyde oxidase
60b
Ziprasidone
CYP: Cytochrome P450; UGT: Uridine diphosphate glucuronosyltransferase.
a
Asenapine is administered sublingually; drinking or eating < 10 minutes after administration may decrease absorption.
b
Decreased absorption when not administered with food.
1
Norclozapine does not appear to have antipsychotic efficacy but it may contribute to anticholinergic effects and hypersalivation.
2
It does not cross the blood-brain barrier. It may contribute to peripheral adverse drug reactions.
Amisulpride
Aripiprazole
Asenapine
Clozapine
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Table 3. Summary of pharmacokinetic drug interactions between newer antidepressants and second-generation antipsychotics.
Antidepressant

Antipsychotic Effect

Proposed mechanism

Fluoxetine

Clozapine

Increase in plasma clozapine concentrations (40-70%)

Risperidone

Increase in plasma concentrations of the active moiety of
risperidone by 75%

Olanzapine

No change or minimal increase in plasma olanzapine
concentrations
Increase by 45% in plasma concentrations of aripiprazole

Inhibition of various CYP
isoforms (CYP2D6,
CYP2C19 and CYP3A4)
Inhibition of CYP2D6
and, to a lesser extent,
CYP3A4
Inhibition of CYP2D6

Aripiprazole
Iloperidone
Paroxetine

Clozapine
Risperidone
Aripiprazole
Iloperidone

Fluvoxamine

Clozapine
Olanzapine
Risperidone
Quetiapine
Aripiprazole
Asenapine

Inhibition of CYP2D6
and CYP3A4
iloperidone Inhibition of CYP2D6

Increase (up to 2-fold) in plasma
concentrations
Increase in plasma clozapine concentrations (20-40%)
Increase in plasma concentrations of the active moiety of
risperidone by 40-50%
Increase in plasma concentrations of aripiprazole by 4050%
Increase (up to 2-fold) in plasma iloperidone
concentrations
Increase (up to 5-10-fold) in plasma clozapine
concentrations

References
37-40
41, 42
43
46
25, 26

Inhibition of CYP2D6
Inhibition of CYP2D6

38, 50, 51
48, 49

Inhibition of CYP2D6

52, 53

Inhibition of CYP2D6

25, 26

Inhibition of CYP1A2
and, to a lesser extent,
CYP2C19 and CYP3A4
Increase (up to 2-fold) in plasma olanzapine concentrations Inhibition of CYP1A2
No significant changes in plasma risperidone
Inhibition of CYP2D6
concentrations at fluvoxamine dosage of 100 mg/day,
and CYP3A4
increase by 26% at fluvoxamine dose of 200 mg/day
Increase in plasma concentrations of quetiapine by 159%
Inhibition of CYP3A4
Decrease by 40% in systemic clearance of aripiprazole
Inhibition of CYP3A4
Increase by 29% in the AUC of asenapine at fluvoxamine
Inhibition of CYP1A2
dosage of 50 mg/day

51, 54-58
63-66
68
45
53
25, 26
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Sertraline

Risperidone

Citalopram/escitalopram Aripiprazole
Duloxetine

Risperidone
Olanzapine

Increased plasma concentrations of risperidone (36-52%) only
at high doses of sertraline (150 mg/day)

Inhibition of CYP2D6

Minimal increase (by 20%) in plasma concentrations of
Inhibition of CYP2D6
aripiprazole and dehydroaripiprazole
Minimal increase (by 26%) in plasma concentrations of the Inhibition of CYP2D6
active moiety of risperidone
No change or minimal increase in plasma olanzapine
Inhibition of CYP2D6 (?)
concentrations

AUC: Area under the curve; CYP: Cytochrome P450.

69
46
83
82, 83
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Table 4. Practical summary of newer antidepressants and second-generation antipsychotic (SGA) drug interactions
ANTIDEPRESSANTS
SGAs
OUTCOME
PK DI. Fluoxetine
↑ level several wks1 after adding fluoxetine
1
Aripiprazole, iloperidone, risperidone, ↓ level several wks after D/C fluoxetine
Clozapine, olanzapine
Lurasidone, quetiapine
Asenapine, amisulpride, paliperidone,
ziprasidone
PK DI. Paroxetine
↑ level one wk after adding paroxetine
↓ level one wk after D/C paroxetine
Aripiprazole, risperidone, iloperidone
Clozapine
Asenapine, amisulpride, lurasidone,
olanzapine paliperidone, quetiapine,
ziprasidone
PK DI. Fluvoxamine
↑ level one wk after adding fluvoxamine
↓ level one wk after D/C fluvoxamine
Clozapine
Olanzapine
Asenapine, aripiprazole, iloperidone,
lurasidone, quetiapine, risperidone
Amisulpride, paliperidone,
ziprasidone
PK DI. Sertraline. It may be Aripiprazole, clozapine, iloperidone,
↑ level one wk after adding sertraline
relevant only in high doses
risperidone
↓ level one wk after D/C sertraline

PD DI. Bupropion and
duloxetine

Asenapine, amisulpride, lurasidone,
olanzapine paliperidone, quetiapine,
ziprasidone
Aripiprazole, risperidone, iloperidone

PK DI. Asenapine

Asenapine, amisulpride, clozapine,
lurasidone, olanzapine paliperidone,
quetiapine ziprasidone
Paroxetine, venlafaxine

PD DI. Bupropion

All SGAs

ACTIONS
In the absence of TDM use dose correction factor:2
0.5
0.75
Unknown in clinical conditions
Possibly no clinically relevant changes
In the absence of TDM use dose correction factor:2
0.5
0.8
Possibly no clinically relevant changes
In the absence of TDM use dose correction factor:2
0.1-0.2. Use TDM; varies according to individual
0.5
Caution (not well studied, current approximation
0.5-0.75)
Possibly no clinically relevant changes
A. Be aware
B. Monitor for ADRs (after adding) and lack of
efficacy (after D/C)
C. Consider TDM
Possibly no clinically relevant changes

↑ level one wk after adding bupropion or
duloxetine
↓ level one wk after D/C bupropion or
duloxetine

A. Be aware
B. Monitor for ADRs (after adding) and lack of
efficacy (after D/C)
C. Consider TDM
Possibly no clinically relevant changes

↑ level one wk after adding asenapine
↓ level one wk after D/C asenapine

A. Be aware
B. Monitor for ADRs (after adding) and lack of
efficacy (after D/C)
Be aware

Weight loss
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PD DI. Bupropion
PD DI. Bupropion
PD DI. Mirtazapine
PD DI. Mirtazapine,
paroxetine and reboxetine
PD DI. Desvenlafaxine,
duloxetine, levominalcipran,
milnacipran and venlafaxine
PD DI. Most newer
antidepressants
PD DI. SSRIs

↑ risk for seizures

Be aware

May rarely cause psychotic exacerbations
Weight gain and increased metabolic ADRs
↑ sedation risk from most SGAs

Be aware
A. Be aware
B. Monitor for ADRs

Clozapine, olanzapine, high quetiapine
doses
Clozapine

↑ risk for antimuscarinic ADRs

A. Be aware
B. Monitor for ADRs
A. Be aware
B. Monitor for ADRs

Aripiprazole, lurasidone, ziprasidone

Possible additive risk for nausea and
vomiting
Possible additive risk for ↑ QTc

All SGAs (clozapine>olanzapine,
quetiapine >other)3
All SGAs when used in psychosis
All SGAs

SGAs

↑ risk for tachycardia and/or hypertension

Monitor closely
A. Be vigilant (can be lethal)
B. Consider need for ECG
C. Torsades de pointes is very rare but additive risk
factors are family history of sudden death; personal
history of syncopes, arrhythmias or heart conditions; hypokalemia, hypomagnesemia, and coprescription of other medications that ↑ QTc. Cases
are more frequent in females aged > 65 years.
D. In the US, consider legal risk. Some SGAPs
(iloperidone and ziprasidone) have been approved
with warnings after particular concern for QTc
prolongation and FDA asked for more studies. The
FDA requires a QTc warning for the use of high
doses of citalopram. Consider these warnings when
co-prescribing.

ADR: Adverse drug reaction; D/C: Discontinuing; FDA: Food and Drug Administration; PD DI: Pharmacodynamic drug interaction; PK DI:
Pharmacokinetic drug interaction; SGA: Second-generation antipsychotic; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective
serotonin reuptake inhibitor.
1
Norfluoxetine, fluoxetine’s main metabolite, is a more powerful inhibitor than fluoxetine and has a very long half-life. Reaching norfluoxetine
steady-state in an average subject may take up to 2-3 months, and 6 months in a non-average patient.
2
A correction factor is used to modify dosing to account for DI. For example, a correction factor of 0.5 indicates that the substrate dose should be
halved. The recommendations are based on the limited information available.
3
Drugs preceding ">" will produce a more powerful outcome than the drugs listed after “>”.
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PHARMACODYNAMICS FOR NEWER ANTIDEPRESSANT EFFICACY
DEPRESSION1
Inhibitors of noradrenaline and serotonin transporter2

Desvenlafaxine, duloxetine, levominalcipran, milnacipran (not approved in the US) and venlafaxine

Selective inhibitors of the serotonin transporter2
All SSRIs

Selective inhibitors of the serotonin transporter and serotonin receptor antagonists3
Vilazodone and vortioxetine

Inhibitor of the noradrenaline and dopamine transporter2
Bupropion

Selective inhibitor of the noradrenaline transporter2
Reboxetine (not approved in the US)

Other

Mirtazapine4 and agomelatine5 (not approved in the US)

OCD
Inhibitors of the serotonin transporter
SSRIs (not all are approved in the US6)

ANXIETY
Probably the same mechanism as antidepressant action7

Different compounds are approved for different disorders8 but specificity is doubtful

PAIN
Inhibition of the noradrenaline transporter9
Duloxetine and milnacipran are approved in the US for fibromyalgia
Duloxetine is approved in the US for diabetic peripheral neuropathic and chronic musculoskeletal pain

WEIGHT LOSS

Inhibition of the dopamine transporter
Bupropion (not approved in the US)10

SMOKING CESSATION

Inhibition of the dopamine transporter
Bupropion11

ATTENTION-DEFICIT HYPERACTVITY DISORDER

Inhibition of the noradrenaline and dopamine transporter
Bupropion (not approved in the US)12

INSOMNIA
Antagonism of brain H1 receptors

Mirtazapine (not approved in the US; daily sedation can be a problem)

Agonism of brain MT2 receptors

Agomelatine (not approved in the US)

STRESS URINARY INCONTINENCE
Duloxetine (not approved in the US)13

Not well understood, noradrenergic mechanisms are probably important

Figure 1. Pharmacodynamics of efficacy for newer antidepressants
5-HT: Serotonin receptor; α: Alpha adrenergic receptor; H: Histamine receptor; MT: Melatonin
receptors; OCD: Obsessive-compulsive disorder; RCT: Randomized clinical trial; SSRI: Selective
serotonin reuptake inhibitor. References were excluded to reduce the total number of references.
The second author can provide them to interested readers.
1
Different meta-analyses have proposed that 1) escitalopram, mirtazapine, sertraline and
venlafaxine may be more efficacious and that escitalopram and sertraline have the best profiles for
efficacy and acceptability; 2) current evidence does not warrant recommending a particular newer
antidepressant; 3) duloxetine and venlafaxine may have superior efficacy to SSRIs, which
milnacipran may not have; 4) escitalopram may the most effective and cost-effective in primary
care; 5) reboxetine may be less efficacious than other newer antidepressants; and 6) agomelatine
may not be superior to placebo.
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Textbooks usually state that most new antidepressants act by inhibiting reuptake transporters.
Vilazadone is described as a dual-acting serotonergic antidepressant that combines selective 5-HT
reuptake inhibition with partial agonism of the 5-HT1A receptor. Vortioxetine is decribed as
combining 5-HT reuptake inhibition with 5-HT3A and 5-HT7 receptor antagonism, 5-HT1B receptor
partial agonism, 5-HT1A receptor agonism.
4
Different textbooks list different mechanisms of action for mirtazapine. Labbate et al. [33] list
mirtazapine as an α2 adrenergic receptor antagonist but also recognized that it has 5-HT2A and 5HT2C antagonist properties. Other articles and/or textbooks endorse other variants of this theory.
5
Agomelatine is a melatonergic analogue drug acting as a MT1/MT2 agonist and a 5-HT2C
antagonist.
6
Fluoxetine, fluvoxamine, paroxetine and sertraline are approved in the US for OCD.
Antidepressants with dual action such as duloxetine, desvenlafaxine and venlafaxine are used offlabel.Vortioxetine has had inconsistent results in generalized anxiety disorder RCTs.
7
There are few attempts to describe the antidepressant pharmacological mechanism in anxiety
disorders; the literature usually assumes that the various antidepressants work in anxiety using the
same mechanism as in depression.
8
Duloxetine, escitalopram, paroxetine, and venlafaxine are approved for generalized anxiety in the
US. Paroxetine, sertraline and venlafaxine are approved for social anxiety in the US. Paroxetine,
sertraline and venlafaxine are approved for panic disorders in the US. A meta-analysis described the
following antidepressants as significantly superior to placebo for panic disorder patients with the
following increasing order of effectiveness: citalopram, sertraline, paroxetine, fluoxetine, and
venlafaxine for panic symptoms and paroxetine, fluoxetine, fluvoxamine, citalopram, venlafaxine,
and mirtazapine for overall anxiety symptoms. Aside from reboxetine and fluvoxamine, all drugs
were associated with significantly lower dropout rates as compared with placebo. Based on a few
agomelatine RCTs and uncontrolled studies, agomelatonine was considered a promising option
when other pharmacological treatments had failed in anxiety disorders.
9
It is believed that for pain treatment the inhibition of the norepinephrine transporter may be more
important than the inhibition of the serotonin transporter. A review included all antidepressant
RCTs in pain syndromes including fibromyalgia, painful diabetic neuropathy, postherpetic
neuralgia, and neuropathic pain (or painful neuropathy). Although venlafaxine is not approved in
the US for pain, some RCTs support its use. The benefits of duloxetine and milnacipran over
placebo in fibromyalgia are small.
10
A meta-analysis indicated that weight loss with fluoxetine appears to be limited to the acute phase
of treatment. The combinations bupropion-zonisamide and bupropion-naltrexone are being studied
in RCTs for weight loss.
11
Bupropion is approved for smoking cessation in the US.
12
According to a meta-analysis, bupropion is superior to placebo and effective in adults. However,
its acceptability and tolerability were not significantly higher than those of placebo. There is very
limited data on other antidepressants.
13
Duloxetine can significantly improve the quality of life of patients with stress urinary
incontinence, but it is unclear whether or not benefits are sustainable.
3
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PHARMACODYNAMICS FOR NEWER ANTIDEPRESSANT SAFETY1
BRAIN
WEIGHT GAIN2

Mirtazapine>3 paroxetine

Antagonism of brain H1
(antagonism of other receptors including 5-HT2C and M may also be relevant for mirtazapine)
↓ SEIZURE THRESHOLD
Bupropion>3placebo>3 some new antidepressants4

Unknown
DECREASED DOPAMINERGIC ACTIVITY
Akathisia (rare)
SSRIs

Other extrapyramidal symptoms (rare)
Probably all newer antidepressants5

Mechanism is not well understood5
Hyperprolactinemia (rare)
Probably all newer antidepressants6

Mechanism is not well understood6
INCREASED DOPAMINERGIC ACTIVITY
Psychotic exacerbations (rare)
Bupropion7

Inhibition of the dopamine transporter
INSOMNIA
Probably all newer antidepressants except for agomelatine

Different mechanisms8
PERIPHERAL (with/without brain component)
NAUSEA AND VOMITING

Desvenlafaxine, duloxetine and venlafaxine >3SSRIs,3,9 vilazodone10 vortioxetine10>3levominalcipran and milnacipran

Possibly inhibition of the serotonin transporter11
TACHYCARDIA and/or HYPERTENSION12

Desvenlafaxine, duloxetine (no hypertension), levominalcipran, milnacipran, reboxetine and venlafaxine

Inhibition of the noradrenaline transporter
DIARRHEA
Sertraline,13 vilazodone and vortioxetine

Unknown
SEXUAL ADRs

SNRIs and SSRIs14

Serotonergic mechanisms15
HYPERLIPIDEMIA
Secondary to weight gain (see above) and possible direct effects on triglyceride levels
Mirtazapine16

ANTICHOLINERGIC ADRs
(Tachycardia, constipation, dry mouth, urinary retention, blurred vision, ↓ sweating)
Mirtazapine, paroxetine17 and possibly reboxetine18

Antagonism of peripheral muscarinic receptors
URINARY SYMPTOMS (dysuria, urinary retention and sensation on incomplete bladder emptying)
Desvenlafaxine, duloxetine, levominalcipran, milnacipran, reboxetine and venlafaxine

Not well understood, probably noradrenergic mechanisms are important
MYDRIASIS (risk for uncontrolled narrow-angle glaucoma)
Desvenlafaxine, duloxetine, levominalcipran, milnacipran, reboxetine and venlafaxine

Inhibition of the noradrenaline transporter
HYPERHIDROSIS
Desvenlafaxine, duloxetine, levominalcipran, milnacipran, reboxetine and venlafaxine

Not well understood, probably noradrenergic mechanisms are important
DISCONTINUATION SYNDROME (acute headaches, dizziness and nausea)19
Paroxetine and venlafaxine>3other>3fluoxetine>3agomelatine and reboxetine (absent)
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Not well understood19
RISK FOR BLEEDING (rare but potentially lethal):
SSRIs usually combined with other drugs with hemorrhagic risk or delivery or surgery

Serotonin depletion in platelets due to inhibition of serotonin transporter and other mechanisms20
SEROTONIN SYNDROME (very rare but potentially lethal)
Usually require combinations of several drugs increasing serotonin activity

Increased serotonin activity in brain and periphery
SUDDEN CARDIAC DEATH ASSOCIATED WITH ARRYTHMIAS (very rare)
Torsades de pointes
Citalopram, fluoxetine, sertraline21

Antagonism of heart repolarizing potassium channels
Risk for patients with Brugada syndrome22
Fluoxetine, fluvoxamine and paroxetine23

Antagonism of heart sodium, potassium or calcium channel
NEUTROPENIA (rare)
Mirtazapine

Unknown
HYPONATREMIA (rare, more frequent in geriatric females)
Probably all newer antidepressants24

SIADH24
LIVER INJURY
Live enzyme elevations

Agomelatine (up to 5% in 50 mg/day)>3probably rare in all other newer antidepressants

Unknown
Life-threatening liver-injury

Agomelatine, bupropion and duloxetine>3other>3citalopram, escitalopram, paroxetine and fluvoxamine

Poorly understood and considered idiosyncratic (immune-allergic or metabolic)

Figure 2. Pharmacodynamics of safety for newer antidepressants.
5-HT: Serotonin receptor; ADR: Adverse drug reaction; ECG: Electrocardiogram; H: Histamine
receptor; M: Muscarinic receptor; TCA: Tricyclic antidepressant; RCT: Randomized clinical trial;
SIADH: Syndrome of inappropriate antidiuretic hormone; SNRI: Serotonin and noradrenaline
reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor. References were excluded to
reduce the total number of references. The second author can provide them to interested readers.
1
The more comprehensive review comparing new antidepressant safety did not include more
recently marketed compounds.
2
Agomelatine is a 5-HT2C antagonist. Insufficient data is available on long-term treatment to rule it
out as a cause of weight gain. Case reports indicated some patients may gain significant weight with
agomelatine long-term treatment.
3
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
4
A comprehensive literature review described bupropion as the only newer antidepressant
associated with increased seizure risk in RCTs. As a matter of fact, when other newer
antidepressants (including citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine,
sertraline, and venlafaxine) were combined, they appear to have less risk than placebo. Moreover,
animal studies, particularly of fluoxetine, suggest that it may have anti-seizure activity. In case
reports, newer antidepressants other than bupropion have occasionally been associated with
seizures.
5
Extrapyramidal symptoms have been reported with different classes of antidepressants, are not
dose-related, and can develop with short-term or long-term use.
6
Symptomatic hyperprolactinemia has been reported with nearly all antidepressants. Incidence rates
are not clearly established and symptoms were very rare. The mechanism by which antidepressants
may cause hyperprolactinemia is not fully understood, though several theories have been
postulated, such as serotonin stimulation of GABAergic neurons and indirect modulation of
prolactin release by serotonin.
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The literature is somewhat contradictory but, in selected cases, bupropion appears to be associated
with the induction of psychotic symptoms in addition to the precipitation or worsening of an
existing psychotic syndrome.
8
Proposed mechanisms: 1) SSRIs may cause insomnia by 5-HT2 stimulation; 2) SNRIs and
reboxetine may cause insomnia by blocking the noradrenaline transporter; and 3) mirtazapine may
have a reverse-dose response effect with sedation a lower doses and with insomnia at higher doses.
H1 antagonism is predominant at lower doses, while increased noradrenerigic activity is
predominant at higher doses.
9
Nausea and vomiting are the most frequent causes of discontinuation of newer antidepressants
during the first 30 days of treatment. They are 10% more frequent in venlafaxine than in SSRIs.
10
There are no comparisons of vilazodone and vortioxetine with other newer antidepressants. The
estimate of the frequency of nausea is a rough estimate based on placebo-controlled RCTs.
11
Possibly explained by inhibition of the serotonin transporter.
12
In a comprehensive review comparing newer antidepressant safety, venlafaxine was significantly
associated with hypertension when compared with other newer antidepressants. Desvenlafaxine and
milnacipran also appear to cause hypertension. Duloxetine has not been consistently associated
with hypertension; increases in blood pressure have been mild, but caution should be used in
patients with hypertension.
13
Comprehensive reviews and meta-analyses agree that sertraline is associated with more diarrhea
risk than other newer antidepressants. The literature does not provide a mechanistic explanation for
this increased risk.
14
Bupropion and mirtazapine may not be different than placebo. Agomelatine and reboxetine are
probably associated with very low risk for sexual ADRs. Vilazodone appears to have low risk for
sexual ADRs but is associated with more sexual ADRs than placebo.
15
It has been proposed that sexual ADRS may be related to serotonergic stimulation of 5-HT2 and 5HT3 receptors but has a complex origin probably also involving the effect of 5-HT on nitric oxide
production as well as other systems.
16
Mirtazepine may increase triglyceride levels but this has not been well studied.
17
Mirtazepine and paroxetine have low antimuscarinic activity. There is some data that citalopram,
escitalopram, fluoxetine and sertraline may have potential to show antimuscarinic activity in some
circumstances.
18
Reboxetine frequently causes dry mouth and constipation, and more rarely urinary retention. It
has been proposed that the noradrenergic mechanism may explain these antimuscarinic symptoms
because 1) reboxetine’s affinity for muscarinic receptors is too low to be relevant at therapeutic
doses, and 2) no metabolites with greater antimuscarinic activity have been identified.
19
SSRI discontinuation included somatic symptoms such as dizziness, lethargy, and sleep
disturbances, as well as psychological symptoms such as anxiety/agitation, irritability, and poor
concentration. The literature provides very limited information on possible mechanisms.
20
It has been proposed that an SSRI-induced increase in gastric acid secretion may explain the
gastrointestinal bleeding risk and that SSRI-related effects on platelet reactivity, endothelial
reactivity, and inflammatory markers may explain the protective effect against ischemic heart
disease.
21
A comprehensive literature review indicated that citalopram (8 cases), fluoxetine (6 cases) and
sertraline (1 case) can rarely be associated with torsade de pointes.
22
Brugada syndrome is identified by a specific ECG pattern (pseudo right bundle branch block and
persistent ST elevation in leads V1 to V3) and high incidence of ventricular fibrillation in the
absence of structural heart disease. Brugada syndrome is a channelopathy explained by genetic
abnormalities in the cardiac sodium, potassium or calcium channels.
23
Fluoxetine, fluvoxamine, and paroxetine should preferably be avoided.
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All newer antidepressants are probably able to cause hyponatremia on rare occasions. It usually
happens in geriatric patients, particularly females. The literature usually describes these cases as
SIADH but it is not clear why antidepressants can cause SIADH.
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PHARMACODYNAMICS FOR SGA EFFICACY
ANTAGONISM OF D2 RECEPTORS AT BASAL GANGLIA AND CORTEX1
Explains antipsychotic efficacy in schizophrenia
All SGAs are approved in the US except amisulpride2

Explains antipsychotic efficacy in other psychoses
None are approved in the US3

Possibly explains anti-manic properties

Aripiprazole, asenapine, olanzapine, quetiapine, risperidone and ziprasidone are approved in the US as montherapy4

Possibly explains postulated mood-stabilizing properties (maintenance in bipolar disorder)
Aripiprazole and olanzapine are approved in the US as monotherapy5

Possibly explains anti-irritability action in autism
Aripiprazole and risperidone are approved in the US

Possibly explains postulated anti-OCD properties when added to serotonergic
antidepressants
None are approved in the US but reasonable data exist on risperidone and quetiapine

DEPRESSION
Treatment of bipolar depression

Lurasidone and quetiapine are approved in the US as monotherapy6

Adjunctive therapy of treatment-resistant depression
Aripiprazole, quetiapine, olanzapine are approved in the US7

Different theories on mechanism of action8
Figure 3. Pharmacodynamics of efficacy for SGAs
5-HT: Serotonin receptor; α: Alpha adrenergic receptor; AP: Antipsychotic; D: Dopamine receptor;
OCD: Obsessive-compulsive disorder; RCT: Randomized clinical trial; SGA: Second-generation
antipsychotic. This figure is an update from Figure 4 in a prior article [35]. References were
excluded to reduce the total number of references. The second author can provide them to interested
readers.
1
All APs are D2 antagonists except aripiprazole, which is a partial agonist (some authors have
proposed that occasionally aripiprazole can be associated with worsening of psychosis). Brain
imaging studies indicate that antipsychotic efficacy may be associated with D2 antagonism at the
basal ganglia and cortex.
2
Amisulpride is approved in Europe but has not been studied for approval in the US.
3
No SGA is approved for psychosis (or behaviors) in dementing illnesses. Paliperidone is approved
for schizoaffective disorder in the US.
4
Aripiprazole, asenapine, quetiapine, risperidone, and olanzapine have been approved for adjunctive
therapy with lithium or valproate. Other SGAs have not been studied in RCTs.
5
Quetiapine has been approved for adjunctive therapy with lithium or valproate.
6
Lurasidone has been approved for adjunctive therapy with lithium or valproate.
7
Olanzapine is approved in combination with fluoxetine. Risperidone had some positive results in
RCTs.
8
The mechanisms proposed in bipolar depression include: i) a high ratio between 5-HT2A/D2
receptors, and ii) a possible role for 5-HT2A or α2 antagonism. A mechanism proposed for
adjunctive treatment in major depressive disorder is a 5-HT2A antagonism that may be shared by
approved SGAs. Specific compound mechanisms include: i) 5-HT1A partial agonism only for
aripiprazole and norquetiapine, the main active metabolite of quetiapine; ii) 5-HT2C antagonism
and inhibition of the noradrenaline transporter by norquetiapine, and iii) antagonism at presynaptic
α2, 5-HT2C, and 5-HT7 receptors by norquetiapine. Ziprasidone at clinical doses blocks reuptake
of serotonin, noradrenaline and dopamine, which may suggest the potential for antidepressant
properties, but the only ziprasidone trial in bipolar depression indicated this compound had no more
efficacy than placebo.
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PHARMACODYNAMICS FOR SGA SAFETY
BRAIN
EXTRAPYRAMIDAL SYMPTOMS

Amisulpride, paliperidone, risperidone>1 asenapine, iloperidone, lurasidone, olanzapine, ziprasidone>1aripiprazole,
quetiapine>1 clozapine2

Antagonism of D2 receptors at nigrostriatal system2
HYPERPROLACTINEMIA

Amisulpride, paliperidone, risperidone>1 asenapine, iloperidone ,lurasidone, olanzapine, ziprasidone>1 quetiapine,
clozapine>1 aripiprazole3

Antagonism of D2 receptors at tubero-infundibular system4
WEIGHT GAIN

Clozapine, olanzapine>1 asenapine, paliperidone, quetiapine, risperidone >
1
amisulpride, aripiprazole, iloperidone, lurasidone, ziprasidone5

Antagonism of brain H1 (and others including 5-HT2C and M) receptors6
SEDATION
Clozapine >1asenapine, olanzapine >1 quetiapine >1 other SGAs7

Antagonism of brain H1 receptors8
MEMORY IMPAIRMENT
Possible with clozapine9

Associated with high antagonism of brain muscarinic receptors in schizophrenia patients6
↓ SEIZURE THRESHOLD
Clozapine >1 olanzapine, quetiapine >1 other SGAs10

D2, H1 and α1 receptor antagonism, actions at neurosteroids or by pharmacological kindling11
OC SYMPTOMS
Clozapine

Antagonism of serotonergic receptors
PERIPHERAL (with/without brain component)
HYPERGLYCEMIA/HYPERLIPIDEMIA
Clozapine, olanzapine, quetiapine12

Secondary to weight gain (see above)
Direct effects on glucose/lipid metabolism
SEXUAL ADRs

Clozapine, risperidone, olanzapine >1 aripiprazole, quetiapine, ziprasidone13

Hyperprolactinemia (see above) and antagonism of peripheral α, M and H receptors14
ORTHOSTATIC HYPOTENSION
Clozapine, iloperidone, risperidone, quetiapine, ziprasidone15

Antagonism of peripheral α1 receptors
HYPERTENSION
Clozapine

Not well understood; probably involves noradrenergic mechanisms
ANTICHOLINERGIC SYMPTOMS
(Tachycardia, constipation, dry mouth, urinary retention, or blurred vision)
16

Clozapine >1 olanzapine >1 quetiapine

Antagonism of peripheral muscarinic receptors
NAUSEA
Aripiprazole, lurasidone, ziprasidone

Unknown17
SWALLOWING IMPAIRMENT AND ASPIRATION RISK (potentially lethal)
(probably important in intellectual disability and dementia)
Probably all SGAs but not well studied

Unknown18
SUDDEN CARDIAC DEATH ASSOCIATED WITH ARRYTHMIAS (very rare)
Torsades de pointes
Amisulpride, risperidone and ziprasidone19

Antagonism of heart potassium repolarizing channel20
AGRANULOCYTOSIS
Clozapine (<1%)
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Probably immunological
NEUTROPENIA (very rare)
Possibly ALL

Unknown
RISK FOR VENOUS THROMBOEMBOLISM (very rare)
Clozapine> other SGAs21

Not well understood22
RISK FOR HEAT STROKE (very rare)
Most published cases also involve FGAs23

Dopamine antagonism interferes with temperature regulation
Muscarinic antagonism from antiparkinsonian or from AP (see anticholinergic) inhibits sweating
RISK FOR HYPONATREMIA (very rare)
There are case reports of both FGAs and SGAs

It is difficult to establish the relationship with APs since 2/3 patients had polydipsia
LIVER ENZYME ELEVATIONS
Clozapine and olanzapine (<5%) >1 probably rare in all other SGAs

Unknown

Figure 4. Pharmacodynamics of safety for SGAs
5-HT: Serotonin receptor; ADR: Adverse drug reaction; AP: Antipsychotic; D: Dopamine receptor;
FGAP: First-generation antipsychotic; H: Histamine receptor; M: Muscarinic receptor; OC:
Obsessive-compulsive; SGA: Second-generation antipsychotic. This figure is an update from
Figure 5 in a prior article [33]. References were excluded to reduce the total number of references.
The second author can provide them to interested readers.
1
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
2
Data from a comprehensive review supplemented with data on asenapine, iloperidone, and
lurasidone. There are three major extrapyramidal symptoms: acute dystonic reactions, parkinsonian
symptoms and akathisia, which are associated with the same common mechanism of D2 receptor
antagonism of the nigrostriatal system, but minor differences may exist among mechanisms and
compounds. For example, aripiprazole is thought to have little risk for extrapyramidal symptoms
except for akathisia. Any attempt to summarize all 3 extrapyramidal symptoms together is a gross
simplification. However, there is not enough meta-analytic data to compare antipsychotics
according to their risk for causing acute dystonic reactions, for causing parkinsonian symptoms, or
for causing akathisia.
3
Data from a comprehensive review supplemented with data on asenapine, iloperidone and
lurasidone.
4
All APs are D2 antagonists except aripiprazole, a partial agonist. The lower propensity of SGAs
(other than aripiprazole) when compared to FGAs to cause extrapyramidal symptoms is explained
by two theories: i) a high ratio between 5-HT2A/D2 receptors, and ii) low affinity and fast
dissociation from D2 (only clozapine and quetiapine will be “atypical” since they are displaced by
endogenous dopamine).
5
Data from a comprehensive review supplemented with data on asenapine, iloperidone and
lurasidone.
6
Studies relating weight gain within various APs and receptor affinity indicate that H1 affinity is the
best predictor of weight gain. Some animal studies indicate that other receptor (particularly 5-HT2C
and muscarinic) antagonism may be needed to produce hyperphagia in animal studies.
7
Data from a comprehensive review supplemented with data on asenapine and iloperidone.
8
H1 antagonism is probably the major contributing mechanism to sedation but other receptor
antagonism may also contribute. Aripiprazole and ziprasidone have also been associated with early
insomnia and activation. It is unknown whether these compounds’ pharmacodynamic differences or
individual susceptibility explain this activation.
9
Antagonism of M1 and M2 receptors has been associated with impaired learning and memory in
animal studies. It is difficult to detect cognitive impairment in the context of schizophrenia but high
antimuscarinic activity was associated with worse memory functioning in an AP meta-analysis.
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Clozapine had a worse profile than risperidone and olanzapine. Clozapine has definitively high
antimuscarinic activity. Olanzapine and high doses of quetiapine may also be associated with
clinically relevant antimuscarinic activity. Thus, olanzapine and high doses of quetiapine may
occasionally be associated with memory impairment.
10
A comprehensive review provided no comparative data on amisulpride, asenapine, iloperidone, or
lurasidone.
11
Proposed mechanisms.
12
Other SGAs may not have direct effects on glucose or lipid metabolism, but this has not been
completely established.
13
A meta-analysis provided no comparative data on amisulpride, asenapine, iloperidone, or
lurasidone.
14
Priapism is rare but is the most severe sexual ADR and is probably explained by α1 (and possible
α2) receptor antagonism.
15
Clozapine, iloperidone, risperidone, quetiapine, and ziprasidone need dose titration to avoid
orthostatic hypotension. Orthostatic changes are not seen after intramuscular injections of
ziprasidone, so ziprasidone probably has low risk of orthostatic hypotension. Other SGAs with
lower risk for orthostatic hypotension are olanzapine (particularly in intramuscular preparation) and
asenapine.
16
Clozapine causes hypersalivation. It is believed that clozapine may be a partial agonist at the M1
and M3 receptors. Norclozapine, clozapine’s main metabolite, is definitively an allosteric agonist of
M1. In rare cases, severe constipation can lead to AP-induced paralytic ileus and other potentially
lethal complications.
17
Antipsychotics, because of their dopaminergic antagonism, are considered anti-emetic drugs, so it
is not known what mechanism explains the association of these three drugs with nausea in the first
week of treatment. Other SGAs may also occasionally be associated with nausea.
18
There are some cases that dysphagia is associated with extrapyramidal symptoms. It is possible
that clozapine, due to frequent hypersalivation and high risk for sedation, has greater potential to
cause aspiration pneumonia.
19
A recent pharmacoepidemiology study suggested that ziprasidone and amisulpride had potential
torsadogenic risk similar to haloperidol and a review of cases reports proposed that risperidone may
rarely cause torsades de pointes.
20
These channels are encoded by the human ether-a-go-go-related gene (HERG).
21
Based on case reports, a recent review indicated that clozapine may have greater risk than other
SGAs.
22
Several hypotheses have been proposed, such as body weight gain, sedation, enhanced platelet
aggregation, increased levels of antiphospholipid antibodies, hyperprolactinemia and
hyperhomocysteinemia.
23
Most published cases including SGAs also had FGAs co-prescribed.

